Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2016-03-29
2016-04-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
These curves profiles are designed to differentiate benign from malignant lesions. Recently, Mann et al, (2014) showed that increasing the temporal resolution of dynamic acquisitions; lesion enhancement curves over time were more accurate than the curves usually performed.
It seems necessary to work on sequences having better temporal resolution without compromising however spatial resolution.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
New Mammographic Techniques Versus MRI in Assessment of Breast Lesions
NCT06089148
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer
NCT02058758
Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer
NCT03176979
Prospective Radiomics Study for Breast Cancer
NCT06095414
Evaluation of the High-resolution, Contrast Enhanced Low-dose Breast-CT
NCT02798562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3.0 Tesla in Magnetic Resonance Imaging
3.0 Tesla in Magnetic Resonance Imaging
Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.
The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
3.0 Tesla in Magnetic Resonance Imaging
Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.
The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>18 years old
* Assessment on 3.0 Tesla in Magnetic Resonance Imaging
* ECOG performance status ≤ 3
* Ability to provide an informed written consent form
Exclusion Criteria
* Claustrophobia
* Contraindication to the injection of gadolinium contrast medium
* Contraindication to MRI
* Persons deprived of liberty or under supervision
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Cancérologie de Lorraine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
OLDRINI Guillaume, MD
Role: PRINCIPAL_INVESTIGATOR
Institut de Cancérologie de Lorraine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-A00581-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.